Main competitors
Add to a list
1m. EPS revision 1m. Revenue rev. 4m. EPS revision 4m. Revenue rev. 1y. EPS revision 1y. Revenue rev. Divergence of Estimates Nbr of analysts
22
26
21
22
27
24
18
19
19
26
21
26
21
15
18
18
17
15
17
Average 21
Weighted average by Cap. 22
Other Pharmaceuticals